Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.

@article{oki2006HydroxyureaIT,
  title={Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.},
  author={Vladan P {\vC}oki{\'c} and Bojana B. Beleslin-{\vC}oki{\'c} and Melanija Tomi{\'c} and Stanko S. Stojilkovic and Constance Tom Noguchi and Alan N Schechter},
  journal={Blood},
  year={2006},
  volume={108 1},
  pages={184-91}
}
Hydroxyurea is a cell-cycle-specific drug that has been used to treat myeloproliferative diseases and sickle cell anemia. We have recently shown that hydroxyurea, like nitric oxide (NO)-donor compounds, increased cGMP levels in human erythroid cells. We show now that hydroxyurea increases endothelial-cell production of NO; this induction of NO in human umbilical vein endothelial cells (HUVECs) and human bone marrow endothelial cell line (TrHBMEC) is blocked by competitive inhibitors of NO… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 67 references

Similar Papers

Loading similar papers…